Protein Cages Advance for Targeted Medicine

SAN DIEGO, Oct. 1, 2026 /CourierPR/ -- Avimer Bio and the Spanish National Cancer Research Centre (CNIO) have published a significant advance in the field of protein cage design in the Journal of the American Chemical Society (JACS). The research, which addresses a longstanding challenge in designing protein assemblies with predictable shapes, has yielded cubic protein cages with minimal mutations to four trimeric protein blocks, totaling twelve subunits, and reaching molecular masses over 600 kilodaltons while maintaining stability in solution.

The team developed computer algorithms that predict how spiral-shaped protein segments, called alpha helices, bend, allowing scientists to use the natural flexibility of protein molecules during design. This breakthrough overcomes a significant hurdle in previous methods, which required precise shapes and thus structural flexibility was a hurdle for designers.

The research has important implications for the development of targeted medicine. Designed protein cages present multiple copies of therapeutic proteins in controlled arrangements, enabling them to engage cell receptors. Certain receptors require gathering in groups to activate a signaling pathway, and a programmable cage can control this grouping beyond the two binding arms found on a conventional antibody. Future designs can display different targeting proteins together to direct activity toward selected cell populations.

The potential applications of this technology are broad, including autoimmune conditions such as rheumatoid arthritis and ulcerative colitis, where engaging selected immune cells can help control inflammation. In oncology, therapeutic proteins on a cage can gather receptors that stimulate immune cells to attack tumors.

The platform, which centers on two distinct properties, is designed to be flexible. It requires few changes to natural protein sequences, supporting designs that retain high similarity to human proteins, which can help in evaluating immune responses. Each cage is built from a single type of protein subunit, simplifying production and maintaining consistent composition compared to particles requiring several distinct chains.

The study was conducted by Robin Aglietti and Peter Bowers at Avimer Bio, alongside Todd Yeates, the company's Chief Scientific Officer and Co-Founder. Roger Castells-Graells directed the structural biology team at CNIO during the cryo-electron microscopy analysis.

The research has significant implications for the development of targeted medicine, particularly in autoimmune conditions and oncology. The use of protein cages to control receptor aggregation and the potential for displaying different targeting proteins together to direct activity toward selected cell populations opens new possibilities for therapeutic applications. The platform's design properties, including minimal changes to natural protein sequences and single protein subunit composition, also offer advantages in production and consistency.